Fulgent Reports Second Quarter 2026 Financial Results
Fulgent Genetics, Inc. (FLGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% • GAAP loss of
How this was made
The 30-second read
Why it matters
The most actionable new information is the revised annual revenue guidance and the stated cause: processing delays impacting the collection rate during the final phase of a revenue cycle management and billing system transition. The filing also provides quantified cash, repurchase activity, and assumptions behind the outlook.
Market read
Traders can reprice the stock around the guidance revision and the operational explanation, then reassess after the scheduled earnings call for any updated collection-rate timeline.
What to watch
The guidance assumes receipt of delayed tax refunds (~$106.1 million) and specific repurchase/capex assumptions; deviations from these could materially change the cash runway and earnings trajectory.
Background
This is an SEC 8-K (Item 2.02) with Exhibit 99.1 covering Fulgent’s Q2 2026 financial results and updated 2026 outlook.
Ticker impact
Fulgent reported Q2 results and revised full-year 2026 revenue guidance to $330.0-$340.0 million due to processing delays.
Likely choppy trading with downside risk if investors focus on collection-rate delays and GAAP losses, partially offset by cash balance and repurchase execution.
The filing discloses a specific guidance revision and the operational reason (processing delays affecting collection rate), plus quantified cash and repurchase amounts that shape near-term expectations.
Market effects
Signals execution risk in lab services revenue-cycle transitions, which can affect sentiment across clinical/lab service providers using similar billing systems.
Limited, primarily company-specific impact for a US-listed healthcare services name.
Low; no cross-border deal or regulatory action disclosed.
Counterpoint
Investors may discount the guidance revision as a temporary systems transition issue, especially with a large cash balance and continued clinical progress commentary.
Key entities
- companyFulgent Genetics, Inc.
NASDAQ-listed laboratory services and therapeutic development company reporting Q2 results and revising 2026 revenue guidance due to revenue-cycle processing delays.
- executiveMing Hsieh
Chairman and CEO quoted on clinical trial progress and AI/digital pathology execution.
- executivePaul Kim
CFO quoted on the revenue guidance revision tied to collection-rate processing delays.
